Literature DB >> 7664180

Determination of CD4 and CD8 lymphocyte subsets by a new alternative fluorescence immunoassay.

T N Denny1, B D Jensen, E I Gavin, A G Louzao, F A Vella, J M Oleske, W Wong.   

Abstract

The purpose of this study was to evaluate a new alternative fluorescence immunoassay method (Zymmune CD4/CD8 Cell Monitoring Kit; Zynaxis, Inc., Malvern, Pa.) for determining the absolute CD4+ and CD8+ T-lymphocyte concentrations in whole blood. The investigation was performed as a two-site comparison of the reference whole blood flow cytometric method with the Zymmune method. In this investigation, a total of 166 patient samples were evaluated of which approximately 20% were from human immunodeficiency virus-positive individuals. The mean value for samples performed by the Zymmune CD4 assay was 1,094 (range, 74 to 2,586) cells per microliters, while the reference method yielded a mean of 890 (range, 35 to 2,033) cells per microliter. The correlation coefficient for regression analysis was 0.940. The mean value for samples performed by the Zymmune CD8 assay was 700 (range, 212 to 1,813) cells per microliter, while the reference method yielded a mean of 546 (range, 82 to 2,158) cells per microliter. The correlation coefficient for regression analysis was 0.921. No site-specific differences or trends in CD4 or CD8 values were seen when the data were analyzed by site of collection. The average precision of the CD4 assay varied from 6 to 14%, corresponding to the high and low concentration ranges. For CD8, the average precision varied from 8.3 to 16% over the respective high to low concentration ranges. We conclude that the Zymmune CD4/CD8 Cell Monitoring Kit method provides absolute CD4+ and CD8+ T-lymphocyte concentrations which are equivalent to those given by the reference flow cytometric method.

Entities:  

Mesh:

Year:  1995        PMID: 7664180      PMCID: PMC170155          DOI: 10.1128/cdli.2.3.330-336.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  17 in total

Review 1.  Application of flow cytometry to the study of HIV infection.

Authors:  A Landay; B Ohlsson-Wilhelm; J V Giorgi
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

Review 2.  Precision and accuracy of absolute lymphocyte counts.

Authors:  J A Koepke; A L Landay
Journal:  Clin Immunol Immunopathol       Date:  1989-07

3.  Pneumocystis carinii pneumonia in infants infected with the human immunodeficiency virus with more than 450 CD4 T lymphocytes per cubic millimeter.

Authors:  E Leibovitz; M Rigaud; H Pollack; R Lawrence; S Chandwani; K Krasinski; W Borkowsky
Journal:  N Engl J Med       Date:  1990-08-23       Impact factor: 91.245

4.  Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS.

Authors:  W Lang; H Perkins; R E Anderson; R Royce; N Jewell; W Winkelstein
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

5.  Evaluation of a new fluorescence immunoassay for CD4+ and CD8+ T cell counts in clinical samples.

Authors:  M J Saez; M de Frutos; P Martinez; V Soriano
Journal:  Vox Sang       Date:  1994       Impact factor: 2.144

6.  CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection.

Authors:  H Masur; F P Ognibene; R Yarchoan; J H Shelhamer; B F Baird; W Travis; A F Suffredini; L Deyton; J A Kovacs; J Falloon
Journal:  Ann Intern Med       Date:  1989-08-01       Impact factor: 25.391

7.  Selective alterations in immunoregulatory lymphocyte subsets in early HIV (human T-lymphotropic virus type III/lymphadenopathy-associated virus) infection.

Authors:  J V Giorgi; P G Nishanian; I Schmid; L E Hultin; H L Cheng; R Detels
Journal:  J Clin Immunol       Date:  1987-03       Impact factor: 8.317

8.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

9.  Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important.

Authors:  J L Malone; T E Simms; G C Gray; K F Wagner; J R Burge; D S Burke
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

10.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Authors:  J L Fahey; J M Taylor; R Detels; B Hofmann; R Melmed; P Nishanian; J V Giorgi
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

View more
  4 in total

1.  Evaluation of TruCount absolute-count tubes for determining CD4 and CD8 cell numbers in human immunodeficiency virus-positive adults. Site Investigators and The NIAID DAIDS New Technologies Evaluation Group.

Authors:  C T Schnizlein-Bick; J Spritzler; C L Wilkening; J K Nicholson; M R O'Gorman
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  A simple manual rosetting method for absolute CD4+ lymphocyte counting in resource-limited countries.

Authors:  Phonethipsavanh Nouanthong; Supansa Pata; Thira Sirisanthana; Watchara Kasinrerk
Journal:  Clin Vaccine Immunol       Date:  2006-05

3.  Evaluation of a method for counting absolute numbers of cells with a flow cytometer.

Authors:  J K Nicholson; D Stein; T Mui; R Mack; M Hubbard; T Denny
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

4.  Inter- and intrainstitutional evaluation of automated volumetric capillary cytometry for the quantitation of CD4- and CD8-positive T lymphocytes in the peripheral blood of persons infected with human immunodeficiency virus. Site Investigators and the NIAID New CD4 Technologies Focus Group.

Authors:  M R O'Gorman; R Gelman
Journal:  Clin Diagn Lab Immunol       Date:  1997-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.